Allocord consists of hematopoietic progenitor cells derived from umbilical cord blood and includes hematopoietic progenitor cells, monocytes, lymphocytes, and granulocytes intended for intravenous infusion. Blood recovered from umbilical cord and placenta is volume reduced and partially depleted of red blood cells and plasma.
ALLOCORD is processed using the PrepaCyte-CB kit reducing the cord blood unit’s red blood cell (RBC) count and plasma volume. The volume of the final product is approximately 35 mL and contains DMSO (10%), dextran 40 (1%), PrepaCyte-CB (approximately 42%), and citrate-phosphate-dextrose (approximately 10%).